A Multi-arm Phase 1b Study of Talquetamab with Other Anticancer Therapies in Participants with Multiple Myeloma

Protocol No
JANSSEN-JNJ-64407564-MONTAL-2
Phase
I
Summary

This is an open-label, nonrandomized, multicenter, Phase 1b study to evaluate the safety and
tolerability of talquetamab combination regimens as well as to identify the safe dose(s) of these combination regimens in the treatment of participants with multiple myeloma. Secondary
objectives include determining the antitumor activity and pharmacokinetics of each combination regimen. Participants will be enrolled into the available treatment regimen(s), each consisting of different combination agent(s) with talquetamab. The different regimens will include participants across varying stages of multiple myeloma treatment

Description
To characterize the safety and tolerability of talquetamab when administered in different combination regimens.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL